Rony T Kondody, Sudhir Rama Varma, Aishwarya Patil, Manjusha Nambiar, Arathi S Nair, Rhea Mathew, Abhishek PT
Rony T Kondody1, Sudhir Rama Varma2, Aishwarya Patil3, Manjusha Nambiar4, Arathi S Nair5, Rhea Mathew6, Abhishek PT7
1Department of Orthodontics and Dentofacial Orthopedics, Sri Rajiv Gandhi College of Dental Sciences, Bangalore.
2Clinical Assistant Professor, Department of Clinical Sciences, Ajman University, Ajman, UAE. Center of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, UAE.
3Department of Oral and Maxillofacial Pathology, S. Nijalingappa Institute of Dental Science and Research. Gulbarga.
4Department of Periodontics. Sri Rajiv Gandhi College of Dental Sciences, Bangalore.
5Department of Conservative Dentistry and Endodontics, Sri Rajiv Gandhi College of Dental Sciences, Bangalore.
6Department of Conservative Dentistry and Endodontics, Sri Rajiv Gandhi College of Dental Sciences, Bangalore.
7Department of Oral and Maxillofacial Surgery. Century International Institute of Dental Science and Research Center, Kasaragod.
Volume - 15,
Issue - 11,
Year - 2022
The world is undergoing its biggest health crisis named coronavirus disease, which is associated with increased proinflammatory cytokine storm, which ultimately leads to various medical complications including acute respiratory distress syndrome. The treatment protocol was always controversial due to the excessive use of corticosteroids in aggressive pneumonia and associated hyperinflammatory conditions.The excessive use, misuse, and rampant use of steroids may lead to various coinfection like mucormycosis which is referred to as black fungus that manifests within the skin and also affects the lungs and brain which may be more fatal. It is necessary to have early diagnosis and management to tackle the severity of post covid coinfection.
Cite this article:
Rony T Kondody, Sudhir Rama Varma, Aishwarya Patil, Manjusha Nambiar, Arathi S Nair, Rhea Mathew, Abhishek PT. Cytokine Storm, Immunomodulators and Mucormycosis in COVID-19: Bench To Bed Side. Research Journal of Pharmacy and Technology. 2022; 15(11):4871-5. doi: 10.52711/0974-360X.2022.00818
Rony T Kondody, Sudhir Rama Varma, Aishwarya Patil, Manjusha Nambiar, Arathi S Nair, Rhea Mathew, Abhishek PT. Cytokine Storm, Immunomodulators and Mucormycosis in COVID-19: Bench To Bed Side. Research Journal of Pharmacy and Technology. 2022; 15(11):4871-5. doi: 10.52711/0974-360X.2022.00818 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-11-3
1. Kondody RT, Sana S, Reddy R, Fatima A, Bangi SL. Coronavirus Disease 2019- Challenges Today and Tomorrow in Orthodontic Practice: A Review. Turk J Orthod 2021;34(1):61-7.
2. Mehta S, Pandey A. Rhino‑orbital mucormycosis associated with COVID‑19. Cureus 2020;12:10726.
3. Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug‑resistant Candida auris infections in critically Ill coronavirus disease patients, India, April–July 2020. Emerg Infect Dis 2020;26:2694‑6.
4. Mekonnen ZK, Ashraf DC, Jankowski T, Grob SR, Vagefi MR, Kersten RC et al. Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome. Ophthalmic Plast Reconstr Surg. 2021;37(2):40-80.
5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
6. Kim JY, Ko JH, Kim Y, Kim YJ, Kim JM, Chung YS et al. Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea. J Korean Med Sci. 2020;35(7):86.
7. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020;111:102452.
8. Hirano T, Murakami M. COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020;52(5):731–3.
9. Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40:37
10. Rello J, Storti E, Belliato M, Serrano R. Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J. 2020;55(5):2001028.
11. Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Ralph ZJ. Invasive fungal diseases during COVID-19: we should be prepared. J Mycol Med 2020;30:100971
12. Chakrabarti A, Denning DW, Ferguson BJ, Ponikau J, Buzina W, Kita H et al. Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. Laryngoscope 2009;119:1809–18
13. Scheckenbach K, Cornely O, Hoffmann TK, Engers R, Bier H, Chaker A et al. Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis. Auris Nasus Larynx 2010;37:322–8
14. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020;S1473–3099:30086–4
15. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med. 2020;173(4):262-267.
16. Winichakoon P, Chaiwarith R, Liwsrisakun C, Salee P, Goonna A, Limsukon A et al. Negative nasopharyngeal and oropharyngeal swabs do not rule out COVID-19. J Clin Microbiol 2020;58:e00297-20
17. Patel R, Babady E, Theel ES, Storch GA, Pinsky BA, St George K et al. Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: Value of diagnostic testing for SARS–CoV-2/COVID-19. Am Soc Microbiol 2020;11:e00722-20.
18. Chatenoud L, Ferran C, Bach JF. The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation. Curr Top Microbiol Immunol 1991;174:121-134.
19. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893;105:487-511.
20. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med 2020; 383:2255-2273
21. Mustafa MI, Abdelmoneim AH, Mahmoud EM, Makhawi AM. Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code Designed Detergent Free Chemokine Receptors.Mediators Inflamm 2020;2020:8198963
22. Zhang Y, Yu L, Tang L, Zhu M, Jin Y, Wang Z et al.,. A promising anti-cytokine storm targeted therapy for COVID-19: the artificial-liver blood-purification system. Engineering (Beijing) 2021;7(1):11-13.
23. Ouyang Y, Yin J, Wang W, Shi H, Shi Y, Xu B et al. Downregulated gene expression spectrum and immune responses changed during the disease progression in COVID-19 patients. Clin Infect Dis. 2020;71(16):2052–2060
24. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71(15):769-777.
25. Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med 2015;373:929-938.
26. Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother 2001;24:287-293.
27. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625-638.
28. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA neurol. 2020;77(6):683–690.
29. Cabello-Verrugio C, Morales MG, Rivera JC, Cabrera D, Simon F. Renin-angiotensin system: an old player with novel functions in skeletal muscle. Med Res Rev. 2015;35(3):437–463.
30. Sahu KK, Kumar R. Preventive and treatment strategies of COVID-19: from community to clinical trials. J Family Med Prim Care. 2020;9(5):2149–2157.
31. Khokra SL, Parashar B, Dhamija HK, Bala M. Immunomodulators: Immune System Modifiers. Research J. Pharm. and Tech. 5(2): Feb. 2012;169-174.
32. Burrage DR, Koushesh S, Sofat N. Immunomodulatory Drugs in the Management of SARS-CoV-2. Front Immunol. 2020;11:1844
33. Liu J, Zheng X, Huang Y, Shan H, Huang J. Successful use of methylprednisolone for treating severe COVID-19. J Allergy Clin Immunol. 2020;146(2):325–327.
34. Kapugi M, Cunningham K. Corticosteroids. Orthop Nurs. 2019;38(5):336–339.
35. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020;39(7):2085–2094.
36. Hao S., Jin D., Zhang S., Qing R. “QTY code-designed water-soluble Fc-fusion cytokine receptors bind to their respective ligands,” QRB Discovery 2020;1:1–18.
37. Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv/. 2020;4:1307–10.
38. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Napoli RD. Features, Evaluation, and Treatment of Coronavirus (COVID-19) [Updated 2021 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/
39. Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379.
40. Mankar SD, Poonam W, Jejurkar P. Review on Mucormycosis: It is a life Threatening infection. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(4):316-8
41. Nambiar M, Varma R.S, Damdoum M. Post-Covid alliance mucormycosis, a fatal sequel to the pandemic in India. Saudi J Biol Sci. 2021, 28(11); 6461-6464
42. Aniket D, Aishwarya P, Kajal D, Pratik K, Yogesh D, Murgude MM. A Review on Mucormycosis (Black Fungus) and its Recent Study. Asian Journal of Research in Chemistry. 2021; 14(5):393-4
43. Nambiar M, Varma R.S, Jaber M, Sreelatha S.V, Thomas B, Nair S.A. Mycotic Infections-mucormycosis and oral candidiasis associated with covid-19: a significant and challenging association. J oral Micro 2021; 13(1); 1967699
44. Gupta R, Saikhedkar R. Spontaneous Necrosis of the Maxilla in an Immunocompetent Patient: A Case Report. Res. J. Pharmacology and Pharmacodynamics. 2019; 11(3): 89-91
45. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13
46. Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: we should be prepared. J Mycol Med. 2020, 30:100971
47. Kolap MB, Dashwant AV. Mucormycosis. Research Journal of Pharmacology and Pharmacodynamics. 2021; 13(3):89-2
48. Rawson TM, Moore LS, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020;71:2459–68
49. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell LC et al. Dexamethasone in hospitalized patients with Covid-19--preliminary report. N Engl J Med 2021;384:693–704.
50. Aniket D, Sudha J. Mucormycosis its Pathogenesis and Treatment. Research Journal of Science and Technology. 2021; 13(3):205-7
51. Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP. Therapy of Mucormycosis. J Fungi (Basel). 2018;4(3):90.
52. Sholly. CK. An evaluation of Mucormycosis, Outburst. Asian Journal of Nursing Education and Research. 2021; 11(4):591-3
53. Sharma NA. Mucormycosis: Why Incidence Rate is more in Covid -19 patients. Asian Journal of Nursing Education and Research. 2021; 11(4):599-0
54. Biradar KV, Pawar A. Corticosteroids and way of inflammation. Research J. Pharmacology and Pharmacodynamics. 2012; 4(1): 45-54.
55. Gupta R, Saikhedkar R. Spontaneous Necrosis of the Maxilla in an Immunocompetent Patient: A Case Report. Res. J. Pharmacology and Pharmacodynamics. 2019; 11(3): 89-91
56. Rani EJ. Alcohol and Covid – 19. Int. J. of Advances in Nur. Management. 2020; 8(4):341-344